高PCV13覆盖率下儿童疫苗型侵袭性肺炎球菌病持续存在:血清型3的作用
西班牙加泰罗尼亚三所儿科转诊医院2018–2023年回顾性观察研究,纳入206例接种PCV13的侵袭性肺炎球菌病患儿。完全接种者中48.0%符合疫苗失败定义,血清型3占疫苗失败的84.7%并导致全部突破性感染,多与复杂性肺炎相关。
要点
- 高PCV13覆盖率下,完全接种儿童疫苗失败比例仍达48.0%,主要由血清型3驱动。
- 血清型3占疫苗失败的84.7%和全部突破性感染,且与复杂性肺炎强相关。
- 多数病例无基础疾病,81.2%仅通过实时PCR确诊,提示分子诊断的重要性。
核心结论
- 在PCV13持续高覆盖率地区,符合疫苗失败流行病学定义的病例占儿科PCV13型IPD的相当比例,且主要由血清型3驱动。
- 研究提示需重视分子诊断、持续监测及开发对血清型3保护更佳的疫苗。
研究设计与样本
- 回顾性观察研究,纳入西班牙加泰罗尼亚三所儿科转诊医院2018–2023年<18岁IPD患儿,期间PCV13覆盖率>96%。
- 识别符合疫苗失败和突破性感染流行病学定义的PCV13血清型病例,并与PCV13普及前时期(2012–2016年)病例比较。
- 分析临床、疫苗接种相关、流行病学、微生物学及分子变量,采用单变量和多变量logistic回归模型。
主要发现
- 206例接种PCV13的IPD患儿中,177例完全接种者中85例(48.0%)为疫苗失败,29例未完全接种者中2例(6.9%)为突破性感染。
- 血清型3占疫苗失败的84.7%和全部突破性感染,并与复杂性肺炎强相关。
- 多数病例无基础疾病,81.2%仅通过实时PCR确诊。
- 多变量分析中,疫苗失败独立关联男性、复杂性肺炎、PCR诊断和2+1接种程序。
- 多位点序列分型显示ST180为血清型3分离株主要谱系;排除血清型3后疫苗失败比例从48.0%降至12.4%。
关键数值与推荐
- 完全接种儿童中疫苗失败比例为48.0%(85/177)。
- 未完全接种儿童中突破性感染比例为6.9%(2/29)。
- 血清型3占疫苗失败的84.7%。
- 81.2%病例仅通过实时PCR确诊。
- 排除血清型3后疫苗失败比例从48.0%降至12.4%。
临床怎么用
- 对高PCV13覆盖率下仍发生IPD的儿童,应警惕血清型3所致疫苗失败,尤其表现为复杂性肺炎者。
- 重视实时PCR等分子诊断手段以提高病原检出和血清型识别。
- 持续开展血清型监测,评估疫苗失败和突破性感染,为疫苗策略更新提供依据。
局限性
- 原文未报告研究局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite widespread implementation of pneumococcal conjugate vaccines (PCVs), invasive pneumococcal disease (IPD) caused by vaccine serotypes continues to occur. Evidence on vaccine failure and breakthrough infections in settings with sustained high PCV13 coverage remains limited. METHODS: We conducted a retrospective observational study including children aged <18 years with IPD admitted to three paediatric referral hospitals in Catalonia, Spain, from 2018 to 2023, a period of high PCV13 coverage (>96%). Cases meeting the epidemiological definitions of vaccine failure and breakthrough infections due to PCV13 serotypes were identified and compared with cases from the pre-universal PCV13 period (2012-2016). Clinical, vaccination-related, epidemiological, microbiological and molecular variables were analysed. Univariable and multivariable logistic regression models were performed. RESULTS: Among 206 PCV13-vaccinated children with IPD, 85 (48.0%) of 177 fully vaccinated were vaccine failure and 2 (6.9%) of 29 incompletely vaccinated children for breakthrough infections. Serotype 3 accounted for 84.7% of vaccine failure and all breakthrough infections and was strongly associated with complicated pneumonia. Most cases occurred in children without underlying conditions and were diagnosed exclusively by real-time PCR (81.2%). In multivariable analysis, vaccine failure was independently associated with male sex, complicated pneumonia, PCR-based diagnosis, and the 2 + 1 schedule. Multilocus sequence typing identified ST180 as the predominant lineage among serotype 3 isolates. Compared with the pre-PCV13 period, the proportion of vaccine failure remained high, although the vaccination protection period was longer during the PCV13 era. Excluding serotype 3 reduced the proportion of vaccine failure from 48.0% to 12.4%. CONCLUSIONS: In a setting with sustained high PCV13 coverage, cases meeting the epidemiological definition of vaccine failure represented a substantial proportion of paediatric PCV13-type IPD and were largely driven by serotype 3. These findings underscore the importance of molecular diagnostics, continued surveillance, and the development of vaccines with improved protection against serotype 3.
引用
- Ciruela P, Broner S, Moraga-Llop F, et al. Persistent vaccine-type invasive pneumococcal disease in children despite high PCV13 coverage: the role of serotype 3. Vaccine. 2026. PMID: 42486053. doi:10.1016/j.vaccine.2026.128940
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。